The £520 million Life Sciences Innovative Manufacturing Fund has officially reopened following its confirmation in last week’s Budget.
The Life Sciences Innovative Manufacturing Fund (LSIMF) is a capital grants fund which aims to build resilience for future health emergencies and capitalise on the UK’s world-leading research and development capabilities. The fund will enhance and accelerate affordable access to mature, new and emerging Life Sciences products for both pandemic and non-pandemic scenarios.
LSIMF will provide up to £520 million in capital grants for investment in the manufacture of human medicines and medical technology (including diagnostics, and MedTech products).
LSIMF is open to all eligible companies, including previous manufacturing grant recipients, as long as the application is for a different project.
Projects with a total cost (including capital expenditure) of at least £8 million are eligible to apply.
Round 1 closes on 29 November 2024, while Round 2 will open on 01 February 2025 and close on 28 February 2025.
You can apply and find out more here.
